Previous close | 55.66 |
Open | 55.41 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 55.41 - 55.41 |
52-week range | 43.31 - 65.36 |
Volume | |
Avg. volume | 26 |
Market cap | N/A |
Beta (5Y monthly) | 2.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Wilmington, DE, April 17, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2024 financial results on Thursday, May 2, 2024 at 8:00 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the “Investors” section. Conference call/Webcast I
Wilmington, DE, March 28, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV) ("Enovis" or the "Company"), an innovation-driven, medical technology growth company, today announced that management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. The presentation is scheduled to begin at 3:45 p.m. Eastern Time on Tuesday, April 9, 2024. A link to the live audio webcast, as well as a replay of this event, will be available on the Company’s website under the
Continued strong momentum with fourth-quarter sales growth of 11%, organic growth of 8% Reported fourth-quarter net income from continuing operations of $0.05 per share with adjusted earnings per diluted share of $0.79Entering 2024 with strong operating momentum and an exciting slate of new product launches Wilmington, DE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the four